These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 16885403)

  • 1. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
    Marckmann P; Skov L; Rossen K; Dupont A; Damholt MB; Heaf JG; Thomsen HS
    J Am Soc Nephrol; 2006 Sep; 17(9):2359-62. PubMed ID: 16885403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
    Marckmann P
    Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
    Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-control study of gadodiamide-related nephrogenic systemic fibrosis.
    Marckmann P; Skov L; Rossen K; Heaf JG; Thomsen HS
    Nephrol Dial Transplant; 2007 Nov; 22(11):3174-8. PubMed ID: 17483196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).
    Khurana A; Runge VM; Narayanan M; Greene JF; Nickel AE
    Invest Radiol; 2007 Feb; 42(2):139-45. PubMed ID: 17220732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB; Maize JC; Woolson RF; Budisavljevic MN
    Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C; Thomsen HS; Marckmann P
    Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
    Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
    J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
    Khurram M; Skov L; Rossen K; Thomsen HS; Marckmann P
    Scand J Urol Nephrol; 2007; 41(6):565-6. PubMed ID: 17934986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
    Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR; Chopard CS; Martin PY; Vallée JP
    Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J
    Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
    [No Abstract]   [Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide.
    Leiner T; Herborn CU; Goyen M
    Eur Radiol; 2007 Aug; 17(8):1921-3. PubMed ID: 17458550
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
    Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
    Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadodiamide-associated nephrogenic systemic fibrosis.
    Karlik SJ
    AJR Am J Roentgenol; 2007 Jun; 188(6):W584; author reply W585. PubMed ID: 17515359
    [No Abstract]   [Full Text] [Related]  

  • 19. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.